Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Total Non-Current Liabilities (2017 - 2024)

CV Sciences' Total Non-Current Liabilities history spans 9 years, with the latest figure at $6.1 million for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities fell 0.97% to $6.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $6.1 million, a 0.97% decrease, with the full-year FY2024 number at $6.1 million, down 0.97% from a year prior.
  • Total Non-Current Liabilities hit $6.1 million in Q4 2024 for CV Sciences, roughly flat from $6.2 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CVSI hit a ceiling of $23.7 million in Q2 2020 and a floor of $6.0 million in Q1 2024.
  • Historically, Total Non-Current Liabilities has averaged $12.8 million across 4 years, with a median of $9.9 million in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 36.51% in 2020 and later tumbled 54.18% in 2023.
  • Tracing CVSI's Total Non-Current Liabilities over 4 years: stood at $19.4 million in 2020, then plummeted by 30.39% to $13.5 million in 2022, then tumbled by 54.18% to $6.2 million in 2023, then fell by 0.97% to $6.1 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for CVSI at $6.1 million in Q4 2024, $6.2 million in Q3 2024, and $6.3 million in Q2 2024.